Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Hundreds of HIV doctors and researchers have called on the Trump administration to reverse its sweeping aid funding cuts, saying they are "doing catastrophic harm" to the global fight against AIDS.

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

A patient told MassLive she was horrified to receive a phone call from her surgeon post-operation saying she should be tested for bloodborne pathogens.

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...